Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
291
resultados
Última actualización
15/07/2026 [08:14:00]
Resultados 150 a 175 de 291
Resumen de: WO2026119202A1
Provided are a variant of glucagon-like peptide-1 (GLP-1) and use thereof. It has been discovered that GLP-1 can be degraded by an insulin-degrading enzyme (IDE), and degradation sites thereof are identified. Moreover, a GLP-1 variant with enhanced stability is designed, and the cellular secretion level and stability of GLP-1 are improved by regulating the IDE.
Resumen de: WO2026121369A1
The present invention provides a method for diagnosing neurodegenerative diseases or providing information for the diagnosis thereof in such a manner that magnetic beads to which a first antibody capable of capturing exosomes such as an anti-CD63 antibody is attached is introduced into the blood of a patient to capture exosomes containing neurodegenerative disease-associated proteins, and then a neurodegenerative disease-associated protein-specific antibody is attached to the captured exosomes to perform detection.
Resumen de: US20260160759A1
0000 Provided herein are methods and systems for multiplex detection and/or measurement of biomarkers of a sample. The methods and systems can be used for rapid disease detection and/or monitoring, vaccine efficacy and immune response monitoring, therapeutic drug monitoring, and/or therapeutic safety and efficacy monitoring.
Resumen de: EP4756429A2
0001 The invention relates to novel methods, kits and use of polypeptides for the detection of antibodies against Bovine Herpes Virus Type 1 (BoHV-1) infection in biological samples including milk, pooled milk and bulk milk.
Resumen de: EP4755889A1
0001 Disclosed are a novel compound for detecting amyloid-beta, and a method of diagnosing a neurodegenerative disease using the same, wherein a compound represented by Formula 1 or a salt thereof according to the present disclosure may specifically bind to amyloid-beta. Due to its high selectivity, the compound or a salt thereof can detect amyloid-beta in plasma with high sensitivity despite interference in detection caused by the presence of other proteins in plasma, and can be utilized for the diagnosis of a neurodegenerative disease or screening for therapeutic agents for a neurodegenerative disease.
Resumen de: WO2024194609A1
The present invention relates to a method for detecting an analyte in a sample suitable for detecting the analyte over a range of concentrations, the method comprising steps (i)-(v). Thus, the present invention provides a method for detecting an analyte in a sample in which only the reporter reagents in the vicinity of the surface of the substrate results in a signal, the signal being a local region of the optical component in the second optical state. It is the set of local regions of the optical component in the second optical state that are detected.
Resumen de: JP2026094866A
【課題】破骨細胞障害性疾患および白質脳症を予防または治療する技術を提供する。【解決手段】オプチニューリン（OPTN）関連物質を有効成分として含有する、破骨細胞障害性疾患および白質脳症の予防または治療剤。【選択図】なし
Resumen de: WO2026115752A1
This urine collection pad (1) comprises a storage member (10) and a holding member (20). The storage member (10) is a member capable of storing urine and has two main surfaces (11) opposite each other. The holding member (20) is a member for holding the storage member (10). The holding member (20) has a poorly permeable layer (22). The poorly permeable layer (22) is a portion having a lower liquid permeability than the storage member (10). The poorly permeable layer (22) covers at least a part of one of the main surfaces of the storage member (10). The storage member (10) is detachable from the poorly permeable layer (22).
Resumen de: CN122163149A
0001 本发明涉及医疗监测与智能预警技术领域，具体是一种多模态融合的CSVD认知功能动态监测与预警系统，解决临床对CSVD患者认知功能与情感障碍的动态、精准、全面监测与预警需求的问题。包括采集获取患者多维数据的多模态数据采集模块；标准化数据的数据预处理模块；提取认知情感特征，构建模型并生成融合特征向量的多模态融合分析模块；实时评估认知功能的认知功能动态监测模块；识别情感状态风险并输出结果的情感状态评估模块、分级预警与建议的风险预警模块、支持数据存储及对接的存储交互模块；可视化呈现监测、评估及预警结果的终端显示模块。本发明通过多模块协同，实现对CSVD患者认知与情感状态的全面监测与精准预警，提升临床应用的针对性和准确性。
Resumen de: WO2024215624A2
This disclosure provides antibodies and methods for preparing and using the same wherein the antibodies bind to PTGFRN on a cell.
Resumen de: CN122150359A
0001 本申请公开了一种三维立体闭合式双极电化学发光侧向流芯片在免疫检测中的应用，所述的芯片包括电极片、试纸条和连接垫；所述的电极片包括两组电极，一组包括阳性驱动电极一、双极电极和阴性驱动电极，另一组是阳性驱动电极二；两组电极分别分布在疏水基底正、反面上；所述阳性驱动电极一与阳性驱动电极二通过导电材料连接。本发明首次将CBPE构建于疏水基底正、反面，形成三维立体CBPE‑ECL电极片，减少了多层电极手动组装所引入的误差，显著提高电极片的一致性与可靠性。
Resumen de: WO2025054524A1
The present disclosure relates in some aspects to methods and compositions for detecting an amyloid-related disease in an individual.
Resumen de: CN122145436A
本发明公开了一种对乙酰胆碱酯酶和黏度双响应的FRET荧光探针及其制备方法和用途，其中FRET荧光探针的结构如下所示：。本发明荧光探针基于荧光共振能量转移（FRET）机制，在短波520 nm响应乙酰胆碱酯酶（AChE），检测限低至0.104 U/L，并在长波680 nm响应黏度，两者波长差高达160 nm，双通道响应无串扰。细胞毒性测试表明该探针的生物相容性良好，共聚焦荧光显微成像实验表明该探针对细胞光稳定性良好，具有双通道同时监测细胞内AChE浓度变化和细胞黏度波动的能力，适用于细胞内AChE浓度变化和黏度波动示踪的共聚焦荧光成像。
Resumen de: CN122145615A
本发明属于生物医药领域，具体涉及抗LMP1抗体及其应用。本发明的抗体对LMP1具有较好的亲和力和/或生物学活性，可用于检测LMP1、诊断或防治与LMP1相关的疾病或病症。
Resumen de: WO2025024265A1
The present application relates to methods for quantifying citrullination and methods that may be used to assess the activity of agents including PAD4 (peptidyl arginine deiminase 4) modulators, such as small molecules or antibodies, for example. In certain embodiments, the methods comprise assessing citrullination of one or more citrullination sites on a protein or a peptide fragment thereof present in a biological sample.
Resumen de: US2025154606A1
Provided herein are methods for predicting characteristics, such as activity, function and/or differentiation state of an in vitro population of neuronal cells, for instance a population of neuronal progenitor cells, as well as methods for selecting and/or implanting an in vitro population of neuronal progenitor cells having desired characteristics. Also provided herein are computing devices for performing the provided methods as well as related compositions, articles of manufacture, and kits, including for use in methods of treating a subject having a neurodegenerative disease, for instance Parkinson's disease.
Resumen de: WO2025037271A1
Provided herein are methods and assays for detecting central nervous system (CNS)-derived tau peptides in blood-based samples from subjects, involving the use of a capture antibody that binds to a tau epitope, and a detection antibody that binds to an epitope comprising amino acids residues that span the junction of Exon 4 and Exon 5 of CNS-derived tau.
Resumen de: US20260152566A1
0000 Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
Resumen de: US20260152551A1
0000 The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.
Resumen de: US20260153520A1
0000 The present invention relates to a method of detecting one or more tissue-derived aggregated proteins in a biological sample.
Resumen de: US20260151513A1
0000 Compositions and methods for the treatment of leukodystrophy, particularly, H-ABC are disclosed.
Resumen de: US20260151494A1
The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.
Resumen de: KR20260081349A
0001a 본 발명은 타겟 물질에 결합할 수 있는 캡쳐 및 상기 캡쳐 상에 결합된 캡쳐 프로프가 고정된 용기에 타겟 물질을 포함하는 시료를 가하여, 상기 캡쳐에 타겟 물질을 결합시키는 단계; 상기 용기를 세척하여, 시료 중 상기 캡쳐에 결합하지 않은 물질을 제거하는 단계; 상기 용기에 상기 캡쳐 프로브에 결합하는 검출 프로브를 가하여, 상기 검출 프로브 중 적어도 일부를 상기 캡쳐 프로브에 결합시키는 단계; 및 상기 용기내 전극에 상기 캡쳐 프로브에 결합하지 않은 검출 프로브를 결합시켜, 결합 전 후의 전기적 신호 변화를 측정하는 단계;를 포함함으로써, 빠르고 간편한 방법으로 시료내 타겟 물질의 존부를 확인하고, 그 양을 정량화할 수 있도록 하는 타겟 물질의 검출 방법에 관한 것이다.
Resumen de: WO2026116669A1
The present invention relates to a novel microRNA for in vitro early diagnosis of mild cognitive impairment and Alzheimer's dementia, and a convergence diagnostic cartridge and diagnostic device using same. The novel miRNA of SEQ ID NO: 1 obtained by molecular analysis exhibits differences in expression levels in the plasma of a normal group, a mild cognitive impairment patient group, and an Alzheimer's dementia patient group, and has the effect of reducing the expression levels of mild cognitive impairment- and Alzheimer's dementia-related proteins. Therefore, by using a novel miRNA present in plasma as a molecular diagnostic index in a non-invasive manner, the present invention enables not only early diagnosis of Alzheimer's dementia but also screening for mild cognitive impairment and Alzheimer's dementia.
Nº publicación: AU2024378628A1 04/06/2026
Solicitante:
ADVANCED BRAIN MONITORING INC
ADVANCED BRAIN MONITORING, INC.
Resumen de: AU2024378628A1
It has proven difficult to automate the detection of neurodegenerative disorders in patients. Thus, detection is currently still performed via visual inspection. Accordingly, embodiments automate the detection of neurodegenerative disorders by deriving sleep biomarker(s) from physiological data, acquired while a subject is sleeping, and applying a classifier to the sleep biomarker(s) to output a risk probability for each neurodegenerative disorder. Embodiments also characterize the neurodegenerative disorder(s) by assigning a risk severity based on the risk probability(ies), output by the classifier.
BOPI
Sede Electrónica
